Fig. 1 · Structure

Documents & Downloads

Bendamustine HCl (SDX-105)

Cat. No. A10124 CAS 3543-75-7

Bendamustine Hydrochloride is a small molecule bifunctional DNA alkylating agent, combining a nitrogen mustard functionality with a purine-analog structure. The dense DNA-damaging functionality of Bendamustine differentiates it from other compounds used as antiproliferative agents, and these functionalities are thought to promote cell death through a variety of different pathways including apoptosis and mitotic catastrophe.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In HBL-2 and Namalwa lymphoma cells, bendamustine hydrochloride induced earlier Chk1/Chk2 phosphorylation than 4-hydroperoxy-cyclophosphamide at the authors’ nominal IC50 concentrations. This supports a cellular DNA-damage-response effect; it does not measure direct kinase inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
DNA synthesis (Cell-free assay)

Bendamustine HCl (SDX-105) Research Summary

This section summarizes 2 in vitro studies of Bendamustine HCl (SDX-105) from 1 published reference. In vitro models include HBL-2 mantle-cell lymphoma and Namalwa Burkitt lymphoma cells.

Bendamustine HCl (SDX-105) In Vitro Studies

A 72-hour hematologic cell-line screen showed variable growth inhibition by bendamustine hydrochloride. Myeloma and AML models were relatively weak responders, and the mantle-cell lymphoma lines Granta519 and NCEB-1 were highly resistant. Sensitivity should therefore be evaluated in the intended model. [1]

Hematologic cell-line sensitivity screen

Cell-based study · Panel of 15 hematologic cancer cell lines; Figure 1A displays 13, with TK and B104 DLBCL results described in Results. [1]

Responses varied substantially. Mantle-cell, Burkitt lymphoma and T-ALL models included responsive lines, whereas myeloma and AML models showed relatively weak responses. Granta519 and NCEB-1 were described as highly resistant. These are growth-inhibition endpoints rather than direct binding potency.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell proliferation relative to untreated cells72-hour MTT growth inhibition Variable response; relatively weak activity in myeloma/AML models; Granta519 and NCEB-1 highly resistant.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Various concentrations; no exact dose series transcribed from plotted bars.
Exposure duration
72 hours
Method
Cell proliferation measured by tetrazolium reduction, expressed relative to corresponding untreated cells.
Co-treatment
Single-agent sensitivity screen.
Reported limits
Vehicle and complete concentration series are not specified in the read screen description. No individual IC50 or IC80 values were estimated from bar heights.
Methods and source locations

Compound reported in the paper: Bendamustine hydrochloride; Compound label in the paper: BDM

Evidence concerns the reported SymBio material; no equivalence of formulation or validation of an Adooq lot is established.

Figure 1A and caption; Materials and Methods: Drugs, Cell Lines, Cell Proliferation Assay; first Results subsection

Cell proliferation relative to untreated cells: MTT reduction assay; untreated cells define the reference. Figure 1A reports mean ± SD of three independent experiments. Individual bar heights were not digitized. — Figure 1A and caption; Results: Bendamustine Induces Apoptosis Faster than other Alkylating Agents but does not Exert Sufficient Cytotoxicity against all Tumors

Checkpoint phosphorylation in lymphoma cells

Cell-based study · HBL-2 mantle-cell lymphoma and Namalwa Burkitt lymphoma cells [1]

At the nominal IC50 concentrations used by the authors, bendamustine induced earlier Chk1/Chk2 phosphorylation than 4-hydroperoxy-cyclophosphamide. This is a cellular DNA-damage-response readout and does not establish direct kinase binding or inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Chk1 and Chk2 phosphorylation over timeImmunoblot time course Authors report phosphorylation peaking at 9–18 hours with bendamustine versus after 48 hours with 4-OHCY.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Bendamustine 25 µM; 4-OHCY comparator 2 µM (nominal IC50 doses specified in Methods).
Exposure duration
Time course from 0 to 48 hours (Figure 4A).
Method
Separate single-agent treatments followed by whole-cell lysate immunoblotting.
Co-treatment
No combination in the adopted comparison; 4-OHCY is a separate comparator.
Reported limits
Vehicle, exact number of independent immunoblot experiments and quantitative densitometry are not specified in the read Figure 4A description.
Methods and source locations

Compound reported in the paper: Bendamustine hydrochloride; Compound label in the paper: BDM

Evidence concerns the reported SymBio material; no equivalence of formulation or validation of an Adooq lot is established.

Figure 4A and caption; Materials and Methods: Drugs, Cell Culture, Immunoblotting; Results checkpoint-response subsection

Chk1 and Chk2 phosphorylation over time: Immunoblotting of phosphorylated Chk1 (Ser-296) and Chk2 (Thr-68); GAPDH loading control; Figure 4A includes time zero. Caption describes representative data from multiple independent experiments without an exact count. — Figure 4A and caption; Results: Bendamustine Elicits DNA Damage Response and Subsequent Apoptosis Faster and with a Shorter Exposure Time than other Alkylating Agents; Materials and Methods: Immunoblotting, Cell Culture

Specifications

Manufacturer Adooq Bioscience
CAS Number 3543-75-7
Formula C16H21Cl2N3O2.HCl
Molecular Weight 394.7
Synonyms Ribomustin; Treanda; Treakisym; SDX-105
SMILES
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 69 mg/mL (174.8 mM)
Water 2 mg/mL (5.06 mM)
Ethanol 15 mg/mL (37.99 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bendamustine HCl (SDX-105) Research References

  1. [1] Nobuya Hiraoka, Jiro Kikuchi, Takahiro Yamauchi, et al. Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies PLoS ONE (2014). PMID: 24626203 DOI: 10.1371/journal.pone.0090675 Source material

Added to your cart

View Cart Checkout
Loading...